FDA OKs Breckenridge's ANDA for rizatriptan benzoate

01/2/2013 | Pharmaceutical Business Review Online

Breckenridge Pharmaceutical's abbreviated new-drug application for rizatriptan benzoate tablets received FDA approval. The tablet, manufactured by Natco Pharma, is the bioequivalent of Merck & Co.'s prescription migraine drug Maxalt.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ